Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.60 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 3/20 | 0.55 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.53 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.48 |
| ▸ | TLK2 | Q86UE8 | 7/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | TDO2 | P48775 | 2/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | AKT2 | P31751 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3576565 | 1.00 | JAK3 (0.60) | JAK3LRRK2GSK3BPDPK1NOX4 | |
| SCHEMBL3582735 | 0.90 | JAK3 (0.50) | JAK3LRRK2GSK3BPDPK1NOX4 | |
| SCHEMBL3582738 | 0.90 | JAK3 (0.50) | JAK3LRRK2GSK3BPDPK1NOX4 | |
| SCHEMBL3578101 | 0.90 | JAK3 (0.55) | JAK3LRRK2GSK3BPDPK1NOX4 | |
| SCHEMBL3578104 | 0.90 | JAK3 (0.55) | JAK3LRRK2GSK3BPDPK1NOX4 | |
| SCHEMBL3578699 | 0.81 | JAK3 (0.52) | JAK3LRRK2GSK3BPDPK1NOX4 | |
| SCHEMBL3578693 | 0.81 | JAK3 (0.52) | JAK3LRRK2GSK3BPDPK1NOX4 | |
| SCHEMBL3571572 | 0.81 | PDPK1 (0.55) | JAK3PDPK1TLK2IDO1TDO2 | |
| SCHEMBL3571577 | 0.81 | TLK2 (0.53) | JAK3PDPK1TLK2IDO1TDO2 | |
| SCHEMBL12044119 | 0.80 | JAK3 (0.51) | JAK3LRRK2GSK3BPDPK1NOX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7749530-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| WO-2010075197-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-7692005-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20090208557-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-08-20 | — | — | US | disclosed |
| EP-1902025-A1 | KINASE INHIBITORS | Allergan, Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090208557-A1 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | JAK3 83/4885LRRK2 848/4885GSK3B 491/4885 |
| US-20070032478-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | JAK3 116/4885LRRK2 636/4885GSK3B 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.